Diagnostic tests in urology: percentage of free prostate‐specific antigen (PSA)
What's known on the subject? and What does the study add? Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood. This article illustrates the use...
Gespeichert in:
| Veröffentlicht in: | BJU international 2013-04, Vol.111 (4), p.683-685 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 685 |
|---|---|
| container_issue | 4 |
| container_start_page | 683 |
| container_title | BJU international |
| container_volume | 111 |
| creator | Yi, Yooni Breau, Rodney H. Witiuk, Kelsey Neuberger, Molly M. Dahm, Philipp |
| description | What's known on the subject? and What does the study add?
Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood.
This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not. |
| doi_str_mv | 10.1111/j.1464-410X.2012.11446.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1324387969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1324387969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3956-8953150394869cfc69790d3792ce8e9f71f61e8c4a9da497671261bc912b5f3f3</originalsourceid><addsrcrecordid>eNqNkMtKAzEUhoMoXqqvINkIumjNbZKJC6HeFUFFBXchTU9KynSmTqZodz6Cz-iTmNpat2aTw8l3Tn4-hDAlHZrO4bBDhRRtQclLhxHKUlcI2XlfQZvLh9Xfmmi5gbZiHBKSGjJbRxuMUyJzpjbRw1mwg7KKTXC4gdhEHEo8qauiGkyP8BhqB2VjB4Arj30NgMd1gm0DXx-fcQwu-DRoyyYMoMT794_dg2205m0RYWdxt9DzxfnT6VX79u7y-rR723ZcZ7Kd64zTjHAtcqmdd1IrTfpcaeYgB-0V9ZJC7oTVfSu0kooySXtOU9bLPPe8hfbne1Oi10mKbkYhOigKW0I1iYZyJniutNQJzeeoS-FjDd6M6zCy9dRQYmZCzdDMXJmZNzMTan6Emvc0urv4ZdIbQX85-GswAXsLwEZnC1_b0oX4xynGSKZY4o7n3FsoYPrvAObk5vmn5N_vlZEU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1324387969</pqid></control><display><type>article</type><title>Diagnostic tests in urology: percentage of free prostate‐specific antigen (PSA)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yi, Yooni ; Breau, Rodney H. ; Witiuk, Kelsey ; Neuberger, Molly M. ; Dahm, Philipp</creator><creatorcontrib>Yi, Yooni ; Breau, Rodney H. ; Witiuk, Kelsey ; Neuberger, Molly M. ; Dahm, Philipp</creatorcontrib><description>What's known on the subject? and What does the study add?
Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood.
This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2012.11446.x</identifier><identifier>PMID: 23106827</identifier><language>eng</language><publisher>Oxford: Wiley-Blackwell</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor - blood ; Biopsy, Needle ; Decision Making ; diagnostic test ; Diagnostic Tests, Routine - methods ; Disease Progression ; elevated PSA ; Evidence-Based Medicine ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Likelihood Functions ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Patient Education as Topic - methods ; percentage of free prostate‐specific antigen ; Predictive Value of Tests ; prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - therapy ; Risk Assessment ; Sensitivity and Specificity ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; Urology - methods</subject><ispartof>BJU international, 2013-04, Vol.111 (4), p.683-685</ispartof><rights>2012 The Authors. BJU International © 2012 BJU International</rights><rights>2014 INIST-CNRS</rights><rights>2012 The Authors. BJU International © 2012 BJU International.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3956-8953150394869cfc69790d3792ce8e9f71f61e8c4a9da497671261bc912b5f3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2012.11446.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2012.11446.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27220572$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23106827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yi, Yooni</creatorcontrib><creatorcontrib>Breau, Rodney H.</creatorcontrib><creatorcontrib>Witiuk, Kelsey</creatorcontrib><creatorcontrib>Neuberger, Molly M.</creatorcontrib><creatorcontrib>Dahm, Philipp</creatorcontrib><title>Diagnostic tests in urology: percentage of free prostate‐specific antigen (PSA)</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>What's known on the subject? and What does the study add?
Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood.
This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biopsy, Needle</subject><subject>Decision Making</subject><subject>diagnostic test</subject><subject>Diagnostic Tests, Routine - methods</subject><subject>Disease Progression</subject><subject>elevated PSA</subject><subject>Evidence-Based Medicine</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Likelihood Functions</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Patient Education as Topic - methods</subject><subject>percentage of free prostate‐specific antigen</subject><subject>Predictive Value of Tests</subject><subject>prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Risk Assessment</subject><subject>Sensitivity and Specificity</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>Urology - methods</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtKAzEUhoMoXqqvINkIumjNbZKJC6HeFUFFBXchTU9KynSmTqZodz6Cz-iTmNpat2aTw8l3Tn4-hDAlHZrO4bBDhRRtQclLhxHKUlcI2XlfQZvLh9Xfmmi5gbZiHBKSGjJbRxuMUyJzpjbRw1mwg7KKTXC4gdhEHEo8qauiGkyP8BhqB2VjB4Arj30NgMd1gm0DXx-fcQwu-DRoyyYMoMT794_dg2205m0RYWdxt9DzxfnT6VX79u7y-rR723ZcZ7Kd64zTjHAtcqmdd1IrTfpcaeYgB-0V9ZJC7oTVfSu0kooySXtOU9bLPPe8hfbne1Oi10mKbkYhOigKW0I1iYZyJniutNQJzeeoS-FjDd6M6zCy9dRQYmZCzdDMXJmZNzMTan6Emvc0urv4ZdIbQX85-GswAXsLwEZnC1_b0oX4xynGSKZY4o7n3FsoYPrvAObk5vmn5N_vlZEU</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Yi, Yooni</creator><creator>Breau, Rodney H.</creator><creator>Witiuk, Kelsey</creator><creator>Neuberger, Molly M.</creator><creator>Dahm, Philipp</creator><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>Diagnostic tests in urology: percentage of free prostate‐specific antigen (PSA)</title><author>Yi, Yooni ; Breau, Rodney H. ; Witiuk, Kelsey ; Neuberger, Molly M. ; Dahm, Philipp</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3956-8953150394869cfc69790d3792ce8e9f71f61e8c4a9da497671261bc912b5f3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biopsy, Needle</topic><topic>Decision Making</topic><topic>diagnostic test</topic><topic>Diagnostic Tests, Routine - methods</topic><topic>Disease Progression</topic><topic>elevated PSA</topic><topic>Evidence-Based Medicine</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Likelihood Functions</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Patient Education as Topic - methods</topic><topic>percentage of free prostate‐specific antigen</topic><topic>Predictive Value of Tests</topic><topic>prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Risk Assessment</topic><topic>Sensitivity and Specificity</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>Urology - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yi, Yooni</creatorcontrib><creatorcontrib>Breau, Rodney H.</creatorcontrib><creatorcontrib>Witiuk, Kelsey</creatorcontrib><creatorcontrib>Neuberger, Molly M.</creatorcontrib><creatorcontrib>Dahm, Philipp</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yi, Yooni</au><au>Breau, Rodney H.</au><au>Witiuk, Kelsey</au><au>Neuberger, Molly M.</au><au>Dahm, Philipp</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic tests in urology: percentage of free prostate‐specific antigen (PSA)</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2013-04</date><risdate>2013</risdate><volume>111</volume><issue>4</issue><spage>683</spage><epage>685</epage><pages>683-685</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>What's known on the subject? and What does the study add?
Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood.
This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.</abstract><cop>Oxford</cop><pub>Wiley-Blackwell</pub><pmid>23106827</pmid><doi>10.1111/j.1464-410X.2012.11446.x</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2013-04, Vol.111 (4), p.683-685 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1324387969 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological and medical sciences Biomarkers, Tumor - blood Biopsy, Needle Decision Making diagnostic test Diagnostic Tests, Routine - methods Disease Progression elevated PSA Evidence-Based Medicine Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Likelihood Functions Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases Patient Education as Topic - methods percentage of free prostate‐specific antigen Predictive Value of Tests prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - therapy Risk Assessment Sensitivity and Specificity Tumors Tumors of the urinary system Urinary tract. Prostate gland Urology - methods |
| title | Diagnostic tests in urology: percentage of free prostate‐specific antigen (PSA) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A08%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20tests%20in%20urology:%20percentage%20of%20free%20prostate%E2%80%90specific%20antigen%20(PSA)&rft.jtitle=BJU%20international&rft.au=Yi,%20Yooni&rft.date=2013-04&rft.volume=111&rft.issue=4&rft.spage=683&rft.epage=685&rft.pages=683-685&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2012.11446.x&rft_dat=%3Cproquest_cross%3E1324387969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1324387969&rft_id=info:pmid/23106827&rfr_iscdi=true |